Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2021-02-25 Board/Management Inform…
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or resignation of outside directors (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of board management and changes in corporate governance structure. Since it specifically details the appointment of new directors, it is classified as Board/Management Information.
2021-02-25 Korean
공정거래자율준수프로그램운영현황(안내공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure filed with the Korea Exchange (KRX) regarding the company's 'Compliance Program' (CP) and anti-corruption (ISO37001) operational status and future plans. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple announcement of a report (RPA). As it details internal governance, compliance, and regulatory adherence practices, it falls under the 'Regulatory Filings' category as a general corporate disclosure.
2021-02-22 Korean
[기재정정]사업보고서 (2018.11)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Hyundai Pharm Co., Ltd. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes. The document explicitly mentions it is a 'Correction Report' (정정신고) regarding previously submitted financial statements due to accounting errors, which is a standard regulatory procedure for audit reports. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statement correction, nor is it an announcement of a report (RPA) because it contains the full content of the audit and the corrected financial statements. FY 2018
2021-02-18 Korean
[기재정정]사업보고서 (2019.11)
Audit Report / Information Classification · 100% confidence The document is a 'Correction Report' (정정신고) for an 'Independent Auditor's Report' (감사보고서) for Hyundai Pharm. It explicitly details corrections made to previously filed financial statements (Balance Sheet, Income Statement, etc.) and includes the full text of the corrected audit report, financial statements, and notes. Since this is a formal filing of audited financial statements and their subsequent correction, it falls under the category of Audit Report / Information. FY 2019
2021-02-18 Korean
[첨부추가]사업보고서 (2020.11)
Audit Report / Information Classification · 100% confidence The document is a comprehensive financial report titled '재무제표에 대한 감사보고서' (Audit Report on Financial Statements) for Hyundai Pharm Co., Ltd. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. Since it contains the full audited financial statements and the auditor's opinion, it is classified as an Audit Report (AR). FY 2020
2021-02-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a short regulatory filing (1429 characters) titled '감사보고서 제출' (Submission of Audit Report). It provides a summary table of financial data and audit opinions for Hyundai Pharm, but it is an announcement of the submission of the audit report to the regulatory body rather than the full, comprehensive audit report document itself. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement. FY 2020
2021-02-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.